Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury

NCT01355549 | Completed Phase 1

• 1 other identifier: R-677-10
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

Shoulder pain is common in persons with spinal cord injury (SCI). It is most often caused by overuse injuries to the muscles and tendons that can occur during wheelchair propulsion, transfers, and other activities of daily living. Normally, shoulder pain resolves with conservative treatments such non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, naproxen, etc.) and physical therapy. However, when these treatments fail, shoulder surgery may be the only option. Platelet Rich Plasma therapy, or PRP, is a treatment option for non-healing muscle and tendon injuries such as those that cause shoulder pain in persons with SCI. Using one's own blood, cells within the blood called "platelets" are concentrated and then re-injected into the muscle and tendon of the shoulder. These platelets release substances known as "growth factors" that lead to tissue healing. By concentrating the platelets we increase the growth factors up to eight times which will promote the healing of tendons. PRP therapy has shown promise in treating tendon and muscle injuries in able-bodied persons; however, its effectiveness in persons with SCI is unknown. The purpose of this study is to explore the feasibility, safety, and efficacy of PRP therapy for chronic shoulder pain in persons with SCI. The human body has a remarkable ability to heal itself and we hypothesize that re-injecting concentrated platelets will facilitate the natural healing process and will reduce shoulder pain in persons with SCI.

Conditions

Shoulder Pain; Rotator Cuff Tendinitis; Rotator Cuff Syndrome; Spinal Cord Injury

Keywords

Shoulder pain; Rotator cuff disease; Spinal cord injuries; Platelet-rich plasma therapy; Rehabilitation

Outcome Measures

Primary Outcomes (1)

• Numerical Rating Scale (NRS)

  Shoulder pain intensity will also be assessed weekly using a numerical rating scale (NRS). Subjects will be asked to rate their average pain, most severe pain, and least severe pain during the past week using an 11-point scale (i.e. 0-10) anchored at the ends by "no pain" and "worst pain ever experienced." An 11-point NRS measure of pain intensity allows for comparison across clinical trials of chronic pain treatment and is recommended as a core outcome measure for chronic pain clinical trials.

  Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment.

Secondary Outcomes (4)

• Wheelchair User's Shoulder Pain Index (WUSPI)

  Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment.

• Patient Global Impression of Change

  Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment.

• Brief Pain Inventory interference items (BPI-I)

  Baseline and 4 weeks, 8 weeks, 12 weeks, and 24 weeks after the PRP treatment.

• Rotator Cuff Disease Score

  Baseline and at the 12-Week and 24-Weeks Follow-up Visit after the PRP treatment.

Study Arms (1)

Platelet-rich plasma therapy

EXPERIMENTAL

Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.

Biological: Platelet-rich plasma (PRP) therapy

Interventions

Platelet-rich plasma (PRP) therapy BIOLOGICAL

Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.

Also known as: Autologous blood injections

Platelet-rich plasma therapy

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• The subject is male or female, 18 to 60 years of age, inclusive.
• The subject has neurological impairment secondary to a spinal cord injury that occurred at least twelve (12) months prior to the Screening Visit and the level of the injury is between C6 and L5, inclusive.
• The subject is non-ambulatory except for exercise purposes and uses a manual or power wheelchair as his/her primary means of mobility (\> 40 hours/week).
• The subject currently has chronic shoulder pain due to rotator cuff disease in spite of at least 6 months of conservative treatment. Average shoulder pain intensity during the week leading up to the Screening Visit should be at least 5 out of 10 on an 11-point numerical rating scale (NRS; 0, no pain; 10, maximum pain imaginable), in spite of a past history of completing 6 months of conservative treatment. Rotator cuff disease will be defined as pain over the anterior shoulder, with direct palpation and pain at the shoulder with provocative tests for rotator cuff disease that is confirmed by tendinopathic changes on ultrasound imaging.
• The subject is able and willing to comply with the protocol.
• The subject is able to and has voluntarily given informed consent prior to the performance of any study-specific procedures.

You may not qualify if:

• The subject reports prior PRP treatment in the same shoulder;
• The subject reports a history of systemic disorders, such as diabetes or rheumatoid arthritis;
• The subject has contra-indications to the procedure, such as infection, coagulopathy, or is currently taking anti-coagulants;
• The subject reports having a glucocorticoid injection in the past 4 weeks;
• The subject is pregnant (documented by a urine pregnancy test);
• The subject has any medical condition, including psychiatric disease, which would interfere with the interpretation of the study results or the conduct of the study.

Sponsors & Collaborators

• Kessler Foundation: lead

Study Sites (1)

Kessler Institute for Rehabilitation

West Orange, New Jersey, 07052, United States

Location

Related Publications (1)

• Dyson-Hudson TA, Hogaboom NS, Nakamura R, Terry A, Malanga GA. Ultrasound-guided platelet-rich plasma injection for the treatment of recalcitrant rotator cuff disease in wheelchair users with spinal cord injury: A pilot study. J Spinal Cord Med. 2022 Jan;45(1):42-48. doi: 10.1080/10790268.2020.1754676. Epub 2020 May 7.

  PMID: 32379581 DERIVED

MeSH Terms

Conditions

Shoulder Pain; Rotator Cuff Injuries; Spinal Cord Injuries

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Arthralgia; Joint Diseases; Musculoskeletal Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Rupture; Wounds and Injuries; Shoulder Injuries; Tendon Injuries; Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System

Study Officials

• Trevor A. Dyson-Hudson, M.D.

  Kessler Foundation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Interim-Director, Spinal Cord Injury Research

Study Record Dates

• First Submitted: May 16, 2011
• First Posted: May 18, 2011
• Study Start: May 1, 2011
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2012
• Last Updated: January 15, 2013

Record last verified: 2013-01

Locations

US (1)